Q-omics provides the consensus-scored TVP23C-CDRT4 profile across patient tissues and cancer cell-line models. TVP23C-CDRT4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TVP23C-CDRT4 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, TVP23C-CDRT4 RNA expression shows 18,466 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, THCA, and THYM as cancer lineages where TVP23C-CDRT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TVP23C-CDRT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TVP23C-CDRT4 survival associations across molecular data types. TVP23C-CDRT4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TVP23C-CDRT4 RNA expression–survival associations across cancer types. High TVP23C-CDRT4 expression shows unfavorable associations in LUSC, LIHC, HNSC and LGG, but favorable associations in SKCM and UCS. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for TVP23C-CDRT4 RNA expression.
This table summarizes TVP23C-CDRT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TVP23C-CDRT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TVP23C-CDRT4 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, KIRP, CHOL and LUAD. The THCA box plot shows higher TVP23C-CDRT4 RNA expression in normal versus tumor tissue (log2 FC = −0.418, t-test p < 0.001).
This table shows molecular features associated with TVP23C-CDRT4 in patient tissues and cancer cell lines. In patient samples, TVP23C-CDRT4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TVP23C-CDRT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE.
